Studying interventions to prevent the progression from prehypertension to hypertension: does TROPHY win the prize?

نویسندگان

  • Stephen D Persell
  • David W Baker
چکیده

and most individuals with systolic blood pressures in the range of 130–139 mm Hg will develop hypertension. Given the burden of cardiovascular disease and stroke attributable to hypertension, delaying its progression using an intervention in the prehypertension stage would be attractive. Testing whether a temporary treatment alters the progression from prehypertension to hypertension, however, raises specific methodological challenges. The research question is not, “Do antihypertensive medications lower blood pressure?” but rather, “Does temporary treatment alter the subsequent course of an individuals’ blood pressure?” Because the focus is on durable effects after treatment has ended, outcomes must be assessed using only data from the post-treatment period for the intervention and control groups. Using data obtained during the initial active-treatment period to assess outcomes will inevitably give the spurious impression of a sustained difference in blood pressure when this may not exist. The recent Trial of Preventing Hypertension (TROPHY) examined whether treating patients with candesartan for two years resulted in a sustained reduction in blood pressure after candesartan was discontinued. TROPHY reported that treatment with candesartan significantly reduced the risk of incident hypertension over the four-year study interval. However, given the way the study’s primary endpoint was defined, these results are likely invalid. Here we describe how the methods of TROPHY biased the findings in the third and fourth years of the study (when both groups were treated with placebo) so it may have appeared there were persistent differences in incident hypertension and higher blood pressures in the placebo group even if the two groups, in actuality, did not differ. We make recommendations for future trials seeking to demonstrate whether lasting differences in blood pressure can be achieved through short-term interventions.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A specialist in clinical hypertension critiques the TROPHY trial.

T he stated purpose of the Trophy trial was “to examine whether early pharmacologic treatment of patients with “high normal” blood pressure would prevent or delay the development of clinical hypertension.” To this end 809 study subjects from 71 different study centers were randomized to receive either 16 mgms. of candesartan or a placebo for two years. After that, all patients were observed on ...

متن کامل

Preventing the Progression of Prehypertension to Hypertension: Role of Antihypertensives

Recent guidelines for the diagnosis and management of hypertension reversed the historical trend to recommend lower blood pressure (BP) thresholds to diagnose hypertension in high-risk individuals, such as patients with diabetes and elderly patients. The decision to raise the BP thresholds for diagnosis of hypertension in patients with diabetes was mostly based on the findings of the ACCORD tri...

متن کامل

Prevalence of hypertension, prehypertension and related factors among Under 40 years old health, medical and administrative Staffs in Birjand, 2021

Background and Aims: Prehypertension is a warning sign in young people since it is an indicator of the risk of hypertension in adulthood. This study aimed to determine the prevalence of hypertension and prehypertension, as well as their related factors, among health, medical and administrative staff in Birjand, Iran. Materials and Methods: This is a descriptive-analytical cross-sectional study...

متن کامل

An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).

The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long-term benefits of pharmacologic therapy in high-normal blood pressure, or prehypertension are not known, and the long-term effect on health-related quality of life (HRQL) has not been determ...

متن کامل

Prehypertension patient awareness and associated cardiovascular risk factors in an urban population in Iran

Background: This study was to estimate the frequency of prehypertension and to characterize patient awareness and associated cardiovascular risk factors in an urban population in Iran. Methods: During a hypertensive awareness program, a cross-sectional study was conducted on 2036 people. All participants completed a questionnaire about their demographic and anthropometric indices and were as...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • American journal of hypertension

دوره 19 11  شماره 

صفحات  -

تاریخ انتشار 2006